[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-induced-laryngeal-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-induced-laryngeal-obstruction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623238","phase-2-effect-of-ipratropium-bromide-on-eilo-100623238",false,"NCT07394036","Effect of Ipratropium Bromide on EILO","The Effect of Ipratropium Bromide on Exercise-Induced Laryngeal Obstruction (EILO) in Pediatric Patients","Inclusion Criteria:\n\n* Patients must be diagnosed with EILO confirmed by Continuous Laryngoscopy During Exercise\n* Patients must be able to complete exercise testing\n* Patients must report dyspnea\n* Patients must have given assent with parental consent, understand all study procedures, and comply with them for the entire length of the study.\n\nExclusion Criteria:\n\n* Patients that do not have EILO.\n* Patients who did not undergo diagnostic CPET with CLE.\n* Patients with hypersensitivity to atropine or its derivatives due to structural similarity with ipratropium bromide.\n* Patients with a history of atrial flutter and\u002For fibrillation\n* Patients taking anticholinergic medications that cannot be paused for 24 hours.\n* Unable to perform exercise tests\n* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n* Inability or unwillingness of patient or parent\u002Flegally authorized representative to give written informed consent.","ALL","8 Years","17 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.",[27,28],"Exercise-Induced Laryngeal Obstruction","Dyspnea During Activity",[27,30,31],"Shortness of Breath during Exercise","Ipratropium Bromide","NOT_YET_RECRUITING","2026-05-01",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":21},"2026-06-01",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Cook Children's Health Care System","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100552976","prevalence-of-eilo-among-children-with-asthma-100552976","NCT06480084","Prevalence of EILO Among Children With Asthma","The Prevalence of Exercise-Induced Laryngeal Obstruction (EILO) Amongst Children With Asthma' - a Prospective Cross-sectional Study","Inclusion Criteria:\n\n* Age 12 to 18 years\n* Paediatrician diagnosed asthma confirmed with at least one of the following during the last two years: Positive ECT (post-exercise fall in FEV1 \\> 10%) \u002F Positive methacholine test (PC20 value of ≤8 mg\u002FmL) \u002F Bronchodilator reversibility (increase in FEV1 ≥12% and\u002For ≥200 mL following inhalation of 200-400 μg short-acting β2-agonists)\n\nExclusion Criteria:\n\n* Other severe cardiopulmonary disease\n* Inability to perform ECT or CLE test\n* Inability to perform technically acceptable spirometry\n* Asthma exacerbation or respiratory tract infection in the last 2 weeks\n* Short-acting β2-agonists or long-acting β2-agonists use less than respectively 8 and 24 hours before the ECT or CLE test\n* Oral corticosteroid use in the 4 weeks before the ECT or CLE test","12 Years","18 Years",{"count":55,"type":21},200,[57],"NA","The goal of this cross-sectional study is to investigate the prevalence of Exercise Induced Laryngeal Obstruction (EILO) in children with asthma.\n\nThe hypothesis is that the prevalence will be around 15%, which is higher than the prevalence of 5-8% among the general adolescent population. This is based on the increased prevalence of EILO among adult asthmatics.\n\nParticipants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire.",[60,61,62,63,64,65],"Exercise Induced Laryngeal Obstruction","Asthma in Children","Exercise-Induced Bronchospasm","Exercise-Induced Bronchoconstriction","Dyspnea","Larynx","2024-06-26",{"date":68,"type":36},"2024-06-28",{"date":70,"type":21},"2024-08-01",{"date":72,"type":21},"2026-04-30",{"name":74,"class":43},"Medisch Spectrum Twente"]